ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

BSY001

A development code. Also written as “BSY001 for Injection (37.5mg)”, “BSY001 for Injection (75 mg)” and “BSY001 for Injection (150 mg)”.

Its studies are mostly in Smallpox, led by Sinopharm.

Furthest: phase 1, since Jan 9, 20261 company-led study, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinopharm11 open or runningphase 1since Jan 9, 2026Jan 9, 2026none ahead

Also a collaborator on its studies: Beijing Institute of Biological Products.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 9, 2026First study: phase 1 study in SmallpoxFirst studyNCT07377175 · 76 planned · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07377175Smallpox · China1RecruitingFeb 13, 202676

How it is read

Names in the registry

  • “BSY001 for Injection (37.5mg)”, 1 entry
  • “BSY001 for Injection (75 mg)”, 1 entry
  • “BSY001 for Injection (150 mg)”, 1 entry
  • “BSY001 for Injection (200 mg)”, 1 entry
  • “BSY001 for Injection (300 mg)”, 1 entry

Codes read as this program: BSY001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.